Mereo Biopharma Updates Setrusumab Trials and Cost Controls

Mereo Biopharma Group Plc ( (MREO) ) has shared an announcement.

On December 29, 2025, Mereo BioPharma reported that its Phase 3 ORBIT and COSMIC trials of setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta did not meet their primary endpoints of statistically significant reduction in annualized clinical fracture rates versus placebo and bisphosphonates, respectively, although both studies showed strongly significant improvements in bone mineral density and no change in the safety profile. The company said it is conducting further analyses of the data, particularly in the higher-risk pediatric population where bone density gains were associated with a non-significant reduction in fractures, and in response to the outcome it is tightening cost controls, immediately reducing pre-commercial and manufacturing activities for setrusumab, and continuing efforts to extract value from its broader rare-disease portfolio, including ongoing partnering discussions for alvelestat.

The most recent analyst rating on (MREO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.

Spark’s Take on MREO Stock

According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.

Mereo Biopharma Group’s overall stock score reflects significant financial and operational challenges typical of an early-stage biotech firm. The lack of revenue and ongoing cash flow issues weigh heavily on its financial performance. Technical indicators suggest some bearish momentum, although not excessively so. The valuation remains unattractive with a negative P/E ratio and no dividends, indicating limited immediate returns for investors.

To see Spark’s full report on MREO stock, click here.

More about Mereo Biopharma Group Plc

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, including setrusumab for osteogenesis imperfecta (OI), alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2. The company operates through a mix of owned and partnered programs, retaining EU and UK commercial rights for several assets while collaborating with partners such as Ultragenyx, āshibio, ReproNovo and Feng Biosciences, and reported a cash balance of $48.7 million at the end of the third quarter of 2025.

Average Trading Volume: 1,856,660

Technical Sentiment Signal: Buy

Current Market Cap: $367.5M

See more insights into MREO stock on TipRanks’ Stock Analysis page.